New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
05:55 EDTCPB, CPB, LIFE, LIFE, CAH, CAH, JNJ, JNJ, CA, CA, S, S, AVP, AVP, INTC, INTC, SCTY, SCTY, BAC, BAC, UBS, UBS, WYN, WYN, PEG, PEG, MS, MS, BUD, BUD, BAH, BAHAgrion and NASDAQ to co-host a summit
Agrion-Nasdaq Energy & Sustainability Summit is being held in New York on February 19-20.
News For CPB;BUD;MS;PEG;WYN;UBS;BAC;SCTY;INTC;AVP;S;CA;JNJ;CAH;LIFE;BAH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
December 10, 2014
09:12 EDTSRadioShack threatens bankruptcy if cell phone deals not reworked, NY Post says
Subscribe for More Information
07:58 EDTSSprint downgraded to Underperform from Perform at Oppenheimer
Subscribe for More Information
07:44 EDTPEGPSEG management to meet with Deutsche Bank
Field trip to company headquarters to be held in Newark, NJ on December 10 hosted by Deutsche Bank.
06:31 EDTBUDAB InBev to move U.S. sales and marketing base from St. Louis, WSJ reports
Subscribe for More Information
December 9, 2014
16:00 EDTBACOptions Update; December 9, 2014
Subscribe for More Information
14:57 EDTBAC, MSFed to propose rulemaking on risk-based capital surcharges for GSIB banks
Subscribe for More Information
14:42 EDTBAC, MSFed sees setting capital surcharge up to 4.5% for big U.S. banks, Bloomberg says
Bloomberg cites surcharge estimates in Federal Reserve staff memo. Publicly traded companies in the space include Bank of America (BAC), Citigroup (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC).
10:28 EDTSVerizon drops after warning about promotional impact on profits
Subscribe for More Information
09:38 EDTBACActive equity options trading
Subscribe for More Information
09:15 EDTBACBank of America sees Q4 sales and trading revenue down linked-quarter, y/y
Subscribe for More Information
08:06 EDTWYNWyndham Hotel Group enters strategic technology partnership with Sabre
Subscribe for More Information
05:50 EDTJNJPharmacyclics data demonstrates safety, durability response
New, 27-month IMBRUVICA median follow-up data announced by Pharmacyclics (PCYC) support the use of IMBRUVICA over longer periods of time in patients with relapsed/refractory mantle cell lymphoma, or MCL, an aggressive type of lymphoma. More than 30% of IMBRUVICA patients remained progression-free after two years with no new or unexpected adverse events occurring during that time. Nearly half of the 111 patients treated were still living at the time of the data analysis. A second Phase II trial looked at IMBRUVICA's efficacy and safety as a single-agent treatment for MCL patients who previously had received rituximab combination therapy and at least two cycles of bortezomib. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:43 EDTJNJPharmacyclics reports IMBRUVICA data shows 84% PFS rate at one year
Pharmacyclics (PCYC) announced new, longer term data in IMBRUVICA patients with relapsed/refractory chronic lymphocytic leukemia, or CLL, including high-risk CLL patients with deletion 17p. Results from the Phase III RESONATE trial demonstrated an 84% progression-free survival, or PFS, rate in all patients with previously treated CLL or small lymphocytic lymphoma, or SLL, who received IMBRUVICA and a 94% PFS rate in patients who received only one prior therapy at 12 months. Separately, follow-up data was reported from Phase II RESONATE-17, or PCYC-1117, the largest prospective trial dedicated to studying CLL or SLL patients with del 17p. The data showed that IMBRUVICA was associated with an 83% overall response rate, or ORR, at a median follow up of 11.5 months. At 12 months, the estimated PFS was 79%. These results and additional data were presented here at the 56th American Society of Hematology, or ASH, Annual Meeting, highlighting IMBRUVICA's sustained efficacy in relapsed/refractory patients who have received at least one prior therapy. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:27 EDTJNJPharmacyclics IMBRUVICA Phase II combination data shows positive profile
Subscribe for More Information
December 8, 2014
16:00 EDTBACOptions Update; December 8, 2014
Subscribe for More Information
14:56 EDTSMDC Partners climbs for third day after making announcement on CRM unit
Subscribe for More Information
11:30 EDTCAHLeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
06:35 EDTBAC, MSValue of Wall Street's M&A bankers has risen, NY Times says
The value of Wall Street's bankers who advise large companies seems to be increasing, while traders are becoming less valuable, according to The New York Times. Bankers who work on M&A deals are expecting their bonuses to increase, while traders anticipate that their compensation will drop, the newspaper added. Furthermore, banks seem to be going the extra mile to hire top notch bankers, the newspaper stated. Publicly traded large banks include Bank of America (BAC), Citigroup (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC). Reference Link
06:21 EDTMSDeadline for Petsmart bidders extended as lenders put on leash, NY Post reports
Subscribe for More Information
December 7, 2014
14:54 EDTJNJIMBRUVICA data suggests promise in multiple myeloma
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use